Edmondo Robinson
About Edmondo Robinson
Edmondo Robinson, M.D., age 49, has served as an independent director of Ardent Health Partners, Inc. (ARDT) since January 2022. He is a physician-executive with deep credentials in digital health and clinical quality, including roles as Founder/CEO of Downeast Digital and former Chief Digital Officer at Moffitt Cancer Center. Dr. Robinson holds an M.D. from UCLA, an MBA from Wharton, and a master’s in health policy research from the University of Pennsylvania, and remains a practicing academic hospitalist and professor at the University of South Florida. His board qualifications emphasize medical and information management expertise, quality oversight, and audit experience .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Moffitt Cancer Center | Senior Vice President & Chief Digital Officer | Dec 2019–Jan 2024 | Led digital innovation strategy and execution |
| ChristianaCare | Various leadership roles | Jul 2008–Dec 2019 | Operational and clinical leadership |
| Sidney Kimmel Medical College | Clinical Assistant Professor; Associate Professor | Jun 2009–Jun 2017; Jun 2017–Nov 2019 | Academic teaching and clinical leadership |
| Robert Wood Johnson Foundation | Clinical Scholar | Jul 2006–Jun 2008 | Health policy research focus |
| Kaiser Permanente Medical Group | Physician | May 2006–Jun 2008 | Clinical practice |
| Harbor-UCLA Medical Center | Resident Physician | Jul 2003–Jun 2006 | Graduate medical training |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Carriage Services, Inc. (NYSE: CSV) | Director; Compensation, Audit & Corporate Governance Committees | Since Oct 2024 | Public company director; multi-committee governance role |
| TruLite Health | Director | Since Feb 2025 | Health equity technology; private developer |
| Downeast Digital | Founder & CEO | Since Feb 2024 | Digital innovation venture |
| University of Vermont Health Network | Trustee | Since Jan 2024 | Non-profit health system board |
| AHRQ National Advisory Council | Chair | Since Jan 2019 | Federal advisory leadership |
| AT&T Healthcare Advisory Council | Member | Since Jan 2019 | Industry advisory |
| Digital Medicine Society (DiMe) | Strategic Advisory Board | Since Apr 2019 | Digital medicine oversight |
| Moffitt Cancer Center | Academic Hospitalist | Since Dec 2019 | Ongoing clinical practice |
| University of South Florida | Professor of Internal Medicine & Oncologic Science | Since Dec 2019 | Academic appointment |
| Aster Insights | Director | Jan 2020–Dec 2023 | Prior data/analytics board role |
Board Governance
| Dimension | Details |
|---|---|
| Independence | ARDT is a “controlled company” under NYSE rules; Dr. Robinson is independent (all directors except Bonick and Bulgarelli were independent in 2024) . |
| Committees (ARDT) | Audit & Compliance Committee member; Quality Committee chair in 2024 . |
| Meetings & Attendance | Board held 6 meetings; Audit held 7; Quality held 4; each director attended ≥75% of Board/committee meetings served . |
| Audit Committee Report | Signatory to Audit & Compliance Committee Report . |
| Executive Sessions | Non-employee/independent directors meet in executive session; structure reviewed annually . |
Fixed Compensation (Director)
| Item | Amount |
|---|---|
| 2024 Fees Earned or Paid in Cash | $110,000 |
| 2024 Stock Awards (Grant Date Fair Value) | $365,235 |
| 2024 Total Director Compensation | $475,235 |
Director Program Structure (context):
- Annual cash retainer $100,000; committee fees: Audit Chair $30,000/member $15,000; Compensation Chair $20,000/member $10,000; Nominating Chair $15,000/member $7,500; Patient Safety & Quality Chair $20,000/member $10,000 .
- Annual Director RSUs grant value $185,000; 2024 RSUs vest March 31, 2025; Special Director RSUs granted Dec 2024 vest on Dec 12, 2025/2026/2027 .
Performance Compensation (Equity and Vesting)
| Equity Component | Shares/Units | Vesting Schedule | Notes |
|---|---|---|---|
| Outstanding RSUs (as of 12/31/2024) | 22,355 | Annual RSUs vest Mar 31, 2025; Special RSUs vest Dec 12, 2025/2026/2027 | Annual RSUs were pro-rated for 2024 IPO timing . |
| RSUs Scheduled to Vest | 11,562 on Mar 31, 2025 | Time-based vesting | Included in beneficial ownership footnote . |
Note: ARDT director equity awards are time-based RSUs; no option awards or director PRSUs are disclosed for non-employee directors in 2024 .
Other Directorships & Interlocks
| Company | Market | Role | Interlock/Conflict Assessment |
|---|---|---|---|
| Carriage Services, Inc. (CSV) | Public (NYSE) | Director; on audit, compensation, governance committees | Funeral/cemetery services; not a competitor/customer/supplier to ARDT; no related-party transactions disclosed involving Dr. Robinson . |
| TruLite Health | Private | Director | Health equity technology vendor; no ARDT transactions disclosed . |
Expertise & Qualifications
- Medical and digital health expertise: practicing hospitalist; former Chief Digital Officer at a leading cancer center .
- Governance and oversight: chairs ARDT Quality Committee; serves on ARDT Audit Committee; multi-committee experience at CSV .
- Education: M.D. (UCLA); MBA (Wharton); M.S. in Health Policy Research (Penn) .
- Federal and industry advisory experience (AHRQ chair; AT&T Healthcare Advisory; DiMe board) .
Equity Ownership
| Metric | Value |
|---|---|
| Total Beneficial Ownership (shares) | 20,275 (includes 11,562 RSUs vesting Mar 31, 2025) |
| Ownership as % of Shares Outstanding | <1% |
| RSUs Outstanding | 22,355 |
| Pledging/Hedging Disclosed | No pledging disclosed; Company has an Insider Trading Policy . |
| Stock Ownership Guidelines | Non-employee directors: 5× annual cash retainer; compliance required within 5 years post-IPO . |
| Compliance Status (12/31/2024) | All non-employee directors except Sotir and Sen exceeded minimum guideline; Robinson meets/exceeds . |
Governance Assessment
-
Strengths
- Independent director with dual committee roles (Audit member; Quality Chair), indicating strong engagement in financial oversight and patient safety quality governance .
- Solid attendance (≥75%) and documented committee meeting cadence (Audit: 7; Quality: 4 in 2024) supports board effectiveness .
- Meaningful equity alignment via RSUs and adherence to stringent director ownership guidelines (met/exceeded as of 12/31/2024) .
- Cross-industry governance experience (CSV) and federal advisory roles enhance oversight capabilities, especially in quality and digital health .
-
Watch items / potential red flags
- ARDT’s “controlled company” status reduces requirements to maintain a majority-independent board and permits compensation/nominating committees with controlling stockholder designees, which can dilute independent influence; continued monitoring of committee composition and independence is warranted .
- Complex related-party landscape (Ventas Master Lease, Nomination Agreement, Services Agreement with EGI-AM, Pure Health investment) is material at the company level; while no Robinson-specific related-party transactions are disclosed, the audit committee’s role in oversight is critical .
- Multi-commitment profile (clinical, advisory, and external boards) may pose time-allocation risks; however, attendance metrics meet thresholds and committee leadership suggests active engagement .
No director-specific related-party transactions, pledging, loans, or hedging were disclosed for Dr. Robinson; no tax gross-ups or unusual perquisites are reported in director compensation .
Board Governance (Detail)
| Committee | Role | 2024 Meetings | Notes |
|---|---|---|---|
| Audit & Compliance | Member | 7 | Audit committee independence affirmed; audit financial experts designated (Goodyear, DeMichiei) . |
| Patient Safety & Quality of Care | Chair | 4 | Oversees quality/safety strategies, risk, equity of patient care . |
| Nominating & Corporate Governance | Not listed as member | 5 (committee) | Controlled company rights influence composition . |
| Compensation | Not listed as member | 9 (committee) | Controlled company may include non-independent members . |
Director Compensation Structure (Reference)
| Component | ARDT 2024 Program |
|---|---|
| Annual Cash Retainer | $100,000 |
| Annual Director RSUs | $185,000 grant date value; 2024 grants vest Mar 31, 2025 |
| Committee Chair/Member Fees | Audit Chair $30,000/member $15,000; Compensation Chair $20,000/member $10,000; Nominating Chair $15,000/member $7,500; Quality Chair $20,000/member $10,000 |
| Special Director RSUs (2024) | Additional RSUs granted Dec 2024; vest Dec 12, 2025–2027 |
| 2024 Payment Cadence | Cash paid quarterly; RSUs pro-rated for partial year onboarding |
Related Party Transactions (Context)
- ARDT is subject to significant related-party arrangements (Ventas lease and rights; Nomination Agreement and Services Agreement with EGI-AM; Pure Health investment) monitored by the Audit & Compliance Committee; no Robinson-specific related-party transactions disclosed .
Say-on-Pay & Shareholder Feedback (Company-level reference)
- Advisory vote on executive compensation and frequency proposals are presented to shareholders; Board recommends annual frequency .
Summary Implications for Investors
- Robinson’s independence, committee leadership in quality, and audit participation, paired with high engagement and equity alignment, support board effectiveness and investor confidence. The controlled company structure and extensive related-party environment remain governance risk factors at the company level, placing heightened importance on the audit committee’s oversight where Robinson serves .